BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35848760)

  • 1. 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.
    Shiraiwa S; Kikuti YY; Carreras J; Kondo Y; Ohmachi K; Ogawa Y; Kawada H; Sato S; Gion Y; Sato Y; Nakamura N; Ando K
    Am J Surg Pathol; 2022 Aug; 46(8):1017-1024. PubMed ID: 35848760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
    Kohno K; Suzuki Y; Elsayed AA; Sakakibara A; Takahara T; Satou A; Kato S; Nakamura S; Asano N
    Am J Clin Pathol; 2020 Apr; 153(5):571-582. PubMed ID: 31977037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
    Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
    Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
    Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA
    Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders.
    Okatani T; Nishimura MF; Egusa Y; Yoshida S; Nishimura Y; Nishikori A; Yoshino T; Yamamoto H; Sato Y
    J Clin Exp Hematop; 2024 Mar; 64(1):1-9. PubMed ID: 38281745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
    Fisher KE; Ferguson LS; Coffey AM; Merritt BY; Curry JL; Marcogliese AN; Major AM; Kamdar KY; Lopez-Terrada DH; Curry CV
    Haematologica; 2022 Aug; 107(8):1880-1890. PubMed ID: 35081690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology.
    Takahara T; Sakakibara A; Tsuyuki Y; Satou A; Kato S; Nakamura S
    J Clin Exp Hematop; 2023; 63(2):58-64. PubMed ID: 37380470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
    Özdemir S; Ton Ö; Kabukcuoğlu F
    Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.
    Jimenez O; Colli S; Garcia Lombardi M; Preciado MV; De Matteo E; Chabay P
    Cancer Immunol Immunother; 2021 Jun; 70(6):1519-1526. PubMed ID: 33184699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-related Epstein-Barr Virus (EBV)-associated lymphoproliferative disorder--so-called "Hodgkin-like lesion"--of the oral cavity in a patient with rheumatoid arthritis.
    Kikuchi K; Miyazaki Y; Tanaka A; Shigematu H; Kojima M; Sakashita H; Kusama K
    Head Neck Pathol; 2010 Dec; 4(4):305-11. PubMed ID: 20676828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV-positive mucocutaneous ulcer arising in methotrexate-treated rheumatoid arthritis patients: a clinicopathological study of 12 cases with analysis of PD-L1 expression.
    Sawada K; Momose S; Iijima Y; Takahashi T; Kaneko T; Yamamoto W; Yamashita T; Higashi M; Kizaki M; Tamaru JI
    J Clin Exp Hematop; 2023 Jun; 63(2):90-98. PubMed ID: 37245972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
    Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
    Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.